Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs Imatinib in Refractory GIST
NCT00751036Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of nilotinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free Survival at 24 months. Started Jun 2009; status: terminated.
02
Drugs
nilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00751036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751036.